- |||||||||| BP1.4979 / Bioprojet
Trial completion date, Trial primary completion date: Pilot Study on BP1.4979 Effect on Binge Eating Disorders (clinicaltrials.gov) - Apr 15, 2024
P2, N=66, Recruiting,
Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
- |||||||||| BP1.4979 / Bioprojet
Trial completion date, Trial primary completion date: Pilot Study on BP1.4979 Effect on Binge Eating Disorders (clinicaltrials.gov) - Feb 8, 2023
P2, N=66, Recruiting,
Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025 Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
- |||||||||| BP1.4979 / Bioprojet
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Pilot Study on BP1.4979 Effect on Binge Eating Disorders (clinicaltrials.gov) - Mar 8, 2022
P2, N=66, Recruiting,
Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023 Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Mar 2023 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Nov 2022 --> Mar 2023
- |||||||||| BP1.4979 / Bioprojet
Enrollment change, Trial termination: P13-04: Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (clinicaltrials.gov) - Aug 8, 2020
P2, N=29, Terminated,
Not yet recruiting --> Recruiting | Trial completion date: Nov 2022 --> Mar 2023 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Nov 2022 --> Mar 2023 N=91 --> 29 | Recruiting --> Terminated; Study facing recruitment difficulties related to stringent eligibility criteria
- |||||||||| BP1.4979 / Bioprojet
Trial completion date, Trial primary completion date: P13-04: Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (clinicaltrials.gov) - Jul 9, 2019
P2, N=91, Recruiting,
These findings indicate the range of doses that can be used to occupy selectively the DRD over the DRD with BP1.4979 and speak to the use of in vivo imaging approaches in dose finding studies. Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- |||||||||| BP1.4979 / Bioprojet
Trial completion, Trial primary completion date: Efficacy and Safety of BP1.4979 in Smoking Cessation (clinicaltrials.gov) - Jan 22, 2015
P2, N=219, Completed,
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014
- |||||||||| BP1.4979 / Bioprojet
Enrollment closed: Efficacy and Safety of BP1.4979 in Smoking Cessation (clinicaltrials.gov) - Sep 5, 2014
P2, N=250, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2014 Recruiting --> Active, not recruiting
|
